Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eSScape: efgartigimod PH20 SC in adults with systemic sclerosis
2024-514539-67-00Phase 2Authorised
- Sponsor
- argenx
- Start
- Jun 2025
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 23
01
Overview
Phase 2, randomised, double-blind trial of efgartigimod alfa and Placebo-COD Research Private Ltd in systemic sclerosis (SSc) (2 arms), sponsored by argenx. Primary endpoint: Change from baseline in modified Rodnan Skin Score at week 24. Planned start Jun 2025; status: authorised.
02
Drugs
efgartigimod alfaPlacebo-COD Research Private Ltd
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2024-514539-67-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514539-67-00.